These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 9718050)
41. [Prevention of myocardial infarction by chemotherapy]. Toshima H; Adachi K Nihon Rinsho; 1982; 40(11):2465-70. PubMed ID: 6130172 [No Abstract] [Full Text] [Related]
42. [Serum cholesterol during the course of acute coronary events and secondary prevention of coronary heart disease]. Garrido Sanjuán JA; Pía Iglesias G; Sesma Sánchez P An Med Interna; 2001 Sep; 18(9):464-7. PubMed ID: 11715132 [TBL] [Abstract][Full Text] [Related]
43. Reperfusion for acute myocardial infarction: is the future in plastics? Rao SV; Jollis JG Mayo Clin Proc; 2000 Oct; 75(10):991-3. PubMed ID: 11040845 [No Abstract] [Full Text] [Related]
44. Which drugs benefit diabetic patients for secondary prevention of myocardial infarction? DARTS/MEMO Collaboration. MacDonald TM; Butler R; Newton RW; Morris AD Diabet Med; 1998 Apr; 15(4):282-9. PubMed ID: 9585392 [TBL] [Abstract][Full Text] [Related]
45. A specialist in clinical hypertension critiques ALLHAT. Meltzer JI Am J Hypertens; 2003 May; 16(5 Pt 1):416-20. PubMed ID: 12745205 [No Abstract] [Full Text] [Related]
49. Niacin: Time to Believe Outcomes Over Surrogate Outcomes: If Not Now, When? Krumholz HM Circ Cardiovasc Qual Outcomes; 2016 Jul; 9(4):343-4. PubMed ID: 27407051 [No Abstract] [Full Text] [Related]
50. Lipoproteins, cholesterol and serum proteins as predictors of myocardial infarction. PAGE IH; LEWIS LA Circulation; 1959 Dec; 20():1011-27. PubMed ID: 14429760 [No Abstract] [Full Text] [Related]
51. A novel telephone-based system for management of secondary prevention to a low-density lipoprotein cholesterol < or = 100 mg/dl. Robinson JG; Conroy C; Wickemeyer WJ Am J Cardiol; 2000 Feb; 85(3):305-8. PubMed ID: 11078297 [TBL] [Abstract][Full Text] [Related]
52. Rationale and design of MultiSELECt: A European Multicenter Study on the Effect of Lipoprotein(a) Elimination by lipoprotein apheresis on Cardiovascular outcomes. Hohenstein B; Julius U; Lansberg P; Jaeger B; Mellwig KP; Weiss N; Graehlert X; Roeder I; Ramlow W Atheroscler Suppl; 2017 Nov; 30():180-186. PubMed ID: 29096835 [TBL] [Abstract][Full Text] [Related]
54. Mechanisms underlying reduction of clinical events in lipid lowering trials. Mancini GB Can J Cardiol; 1995 May; 11 Suppl C():15C-17C. PubMed ID: 7750043 [TBL] [Abstract][Full Text] [Related]
55. Low total cholesterol and high total mortality in patients with coronary heart disease. Ector H Eur Heart J; 1997 Aug; 18(8):1357-9. PubMed ID: 9458432 [No Abstract] [Full Text] [Related]
57. Secondary prevention trials after acute myocardial infarction. Furberg CD Am J Cardiol; 1987 Jul; 60(2):28A-32A. PubMed ID: 2887098 [TBL] [Abstract][Full Text] [Related]
58. [Value of the analysis of lipoproteins after myocardial infarction]. Dewailly P; Mellin D; Moulin S; Rouget JP; Sezille G; Jaillard J Presse Med; 1983 Jul 9-16; 12(29):1807-10. PubMed ID: 6224195 [TBL] [Abstract][Full Text] [Related]
59. Effects of statins on six-month survival and clinical restenosis frequency after coronary stent deployment. Bunch TJ; Muhlestein JB; Anderson JL; Horne BD; Bair TL; Jackson JD; Li Q; Lappé DL Am J Cardiol; 2002 Aug; 90(3):299-302. PubMed ID: 12127616 [No Abstract] [Full Text] [Related]